


Investment Objective

The Strategy aims to generate long term capital appreciation by creating a focused portfolio of high growth stocks having the potential to grow more than the nominal GDP for next 5-7 years across and which are available at reasonable market prices.

Performance



Performance Attribution Analysis (1 Year Trailing 31st December 2018)

Scrip	Contribution
VIP Industries	0.26%
Glaxosmithkline Consumer Healthcare	0.17%
TTK Prestige	0.09%
Dr Lal PathLabs	0.06%
V-Mart Retail	0.05%
5Paisa Capital	-0.02%
Bayer CropScience India	-0.11%
AU Small Finance Bank	-0.48%
Alkem Laboratories	-0.59%
Suprajit Engineering	-0.68%
Mahanagar Gas	-0.73%
IIFL Holdings	-0.76%
Dhanuka Agritech	-0.96%
Blue Star	-1.00%
Development Credit Bank	-1.10%
Kajaria Ceramics	-1.46%
Dishman Carbogen Amcis	-1.52%
Gabriel India	-1.70%
Lakshmi Vilas Bank	-1.78%
ITD Cementation India	-1.86%
Can Fin Homes	-1.93%
Aegis Logistics	-2.01%
Quess Corp	-2.69%
Birla Corporation	-4.82%

Holdings & Top 5 Sectors

Scrip Names	% Holdings
Development Credit Bank Ltd	9.60
AU Small Finance Bank Ltd	7.20
TTK Prestige Ltd	7.00
Birla Corporation Ltd	6.98
Aegis Logistics Ltd	6.84
Gabriel India Ltd	6.43
Mahanagar Gas Ltd	5.84
Alkem Laboratories Ltd	5.47
Kajaria Ceramics Ltd	4.70
Blue Star Ltd	4.48
Quess Corp Ltd	4.05
Dr Lal Pathlabs Ltd	4.04
Dishman Carbogen Amcis Ltd	4.02
Canfin Homes Ltd	3.91
Lakshmi Vilas Bank Ltd	3.67
ITD Cementation India Ltd	2.67
IIFL Holdings Ltd	2.49
Dhanuka Agritech Ltd	2.17
Bayer Cropscience Ltd	2.10
Suprajit Engineering Ltd	2.04
VIP Industries Ltd	1.71
GlaxoSmithkline Consumer Healthcare Ltd	1.56
V-Mart Retail Ltd	0.98
5Paisa Capital Ltd	0.04

Sectors	% Allocation
Banking & Finance	26.91
Pharmaceuticals	13.54
Oil & Gas	12.68
Consumer Durable	11.70
Cement & Infrastructure	9.65
Cash	-

Market Capitalization

Market Capitalization	% Equity
Large cap	-
Midcap	23
Smallcap	77

Weighted Average Market Cap (Rs)	8394 Crs
----------------------------------	----------

Risk Ratios

3 Year Data	Scheme	Benchmark
Std Dev	16.27%	16.66%
Beta	0.79	1.00
Sharpe Ratio	0.19	0.19
Upside Capture	0.48	1.00
Downside Capture	0.97	1.00

*Portfolio Fundamentals

	TTM	FY19E	FY20E
PAT Growth	19%	17%	26%
RoE	13%	15%	17%
PE	30	26	17

Disclaimers and Risk Factors

IOP Strategy Inception Date: 15th Feb 2010; Data as on 31st December 2018; Data Source: MOAMC Internal Research; RFR – 7.25%; * Earnings as of Sept 2018 quarter and market price as on 31st December 2018
 Please Note: The above strategy returns are of a Model Client as on 31st December 2018. Returns of individual clients may differ depending on time of entry in the Strategy. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns below 1 year are absolute and above 1 year are annualized. Strategy returns shown above are post fees & expenses. The stocks forming part of the existing portfolio under IOP Strategy may or may not be bought for new client. Name of the PMS Strategy does not in any manner indicate its future prospects and returns. The Company names mentioned above is only for the purpose of explaining the concept and should not be construed as recommendations from MOAMC.